Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 11/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401622 | 0.93 | LPAR1 (0.53) | LPAR1KMT2AMEN1MAPTLPAR2 | |
| SCHEMBL5402977 | 0.92 | LPAR1 (0.47) | LPAR1CTSGCMA1KMT2AMEN1 | |
| SCHEMBL5394210 | 0.92 | LPAR1 (0.46) | LPAR1CTSGCMA1KMT2AMEN1 | |
| SCHEMBL5398909 | 0.91 | LPAR1 (0.51) | LPAR1LPAR2 | |
| SCHEMBL5402546 | 0.90 | KMT2A (0.47) | LPAR1CTSGCMA1KMT2AMEN1 | |
| SCHEMBL5394257 | 0.85 | HPGD (0.51) | CTSGCMA1KMT2AMEN1MAPT | |
| SCHEMBL5407075 | 0.85 | LPAR1 (0.45) | LPAR1MAPTALDH1A1 | |
| SCHEMBL5397226 | 0.85 | LPAR1 (0.47) | LPAR1KMT2AMEN1MAPTKDM4E | |
| SCHEMBL5392507 | 0.85 | TAAR1 (0.48) | LPAR1CTSGCMA1KMT2AMEN1 | |
| SCHEMBL5397206 | 0.84 | LPAR1 (0.50) | LPAR1KMT2AMEN1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | LPAR1 17/4885CTSG 1299/4885CMA1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.